Schrodinger, Inc. - SDGR STOCK NEWS

Schrödinger (SDGR) has granted restricted stock units (RSUs) for 4,840 shares of common stock to four newly hired employees on January 20, 2025. The grants were made under the company's 2021 Inducement Equity Incentive Plan and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs feature a four-year vesting schedule: 25% vests after 12 months of continuous service from the vesting commencement date, followed by the remaining balance vesting in three equal yearly installments of 25% each. These inducement grants are governed by award agreements and the company's 2021 Inducement Equity Incentive Plan.

Schrödinger provided an update on its 2024 progress and outlined its 2025 strategic priorities. Key highlights include:

Expanded Collaborations: Schrödinger expanded its research collaboration with Otsuka Pharmaceutical Co., , and its agreement with Novartis, which includes a $150 million upfront payment expected in Q1 2025.

2024 Achievements: The company launched initiatives to enhance its computational platform and introduced LiveDesign Biologics. It published 29 peer-reviewed articles and advanced Phase 1 clinical studies for SGR-1505, SGR-2921, and SGR-3515. The FDA granted Fast Track Designation to SGR-2921.

Collaborations and Investments: Schrödinger announced a $150 million collaboration with Novartis, with potential milestone payments of up to $2.3 billion. Co-founded companies, including Morphic Holding and Ajax Therapeutics, made significant progress in their respective fields.

2025 Strategic Priorities: Schrödinger aims to increase customer adoption of its technology, advance predictive toxicology, and present initial Phase 1 data for SGR-1505, SGR-2921, and SGR-3515.

Schrödinger will release its Q4 and full-year financial results on February 26, 2025.

Schrödinger (SDGR) has granted restricted stock units (RSUs) for 8,365 shares to six newly hired employees on December 12, 2024. The grants were made under the company's 2021 Inducement Equity Incentive Plan and approved by the compensation committee. The RSUs will vest over four years, with 25% vesting after 12 months of continuous service, followed by equal yearly installments of 25% over the next three years. These grants serve as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).

Schrödinger (Nasdaq: SDGR) has announced its upcoming participation in the Piper Sandler 36th Annual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Wednesday, December 4, 2024, at 8:30 a.m. ET. Interested parties can access the live webcast through the 'Investors' section of Schrödinger's website, where it will remain available for approximately 90 days after the event.

Schrödinger (SDGR) has granted restricted stock units (RSUs) for 2,785 shares to four new employees as inducement awards. The grants, made under the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee and comply with Nasdaq Listing Rule 5635(c)(4). The RSUs follow a four-year vesting schedule, with 25% vesting after 12 months of continuous service and the remaining 75% vesting in equal yearly installments over the following three years.

Schrödinger (SDGR) is expanding its computational platform initiative to predict toxicology risk in early drug discovery, receiving an additional $9.5 million from the Bill & Melinda Gates Foundation, following their initial $10 million grant in July 2024. The funding extends to April 2026 and will accelerate access to experimental structures. The technology aims to reduce drug development failures by identifying off-target protein binding risks. Once developed, the tools will be available to Gates Foundation grantees globally and Schrödinger's software customers, supporting drug development for diseases affecting low- and middle-income countries.

Schrödinger (SDGR) reported Q3 2024 financial results with total revenue of $35.3 million, down from $42.6 million in Q3 2023. Software revenue increased 10% to $31.9 million, while drug discovery revenue decreased to $3.4 million. The company announced a new collaboration with Novartis, receiving $150 million upfront with potential milestone payments up to $2.3 billion. Operating expenses rose to $86.2 million, and net loss was $38.1 million. The company updated its 2024 guidance, projecting software revenue growth of 8-13% and drug discovery revenue between $20-30 million.

Schrödinger (SDGR) has announced a significant collaboration with Novartis comprising two major agreements. First, a research collaboration and license agreement where Schrödinger will receive $150 million upfront and is eligible for up to $2.3 billion in milestone payments plus royalties. Second, an expanded three-year software agreement giving Novartis broader access to Schrödinger's computational predictive modeling technology.

The companies will jointly work on multiple development candidates in Novartis's core therapeutic areas. While both companies will share discovery responsibilities, Novartis will handle clinical development, manufacturing, and global commercialization. The royalty structure includes tiered mid single-digit to low double-digit percentages on net sales.

Schrödinger (Nasdaq: SDGR), a company leveraging physics-based computational platforms for therapeutics and materials discovery, has announced its upcoming participation at the Jefferies London Healthcare Conference. The company's management will engage in a fireside chat scheduled for Wednesday, November 20, at 8:30 a.m. GMT (3:30 a.m. ET). Interested parties can access the live webcast through the 'Investors' section of Schrödinger's website, where it will remain available for approximately 90 days after the event.